J.P. Morgan Asset Management today released its seventh annual Global Alternatives Outlook, providing a 12-to-18 month ...

What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

Fintel reports that on January 28, 2025, JP Morgan upgraded their outlook for Ciena (NYSE:CIEN) from Neutral to Overweight.

Ciena (NYSE:CIEN) was upgraded to Overweight from Neutral by J.P. Morgan following a 21% plunge on Monday related to DeepSeek and the market reaction to a wide array of stocks connected to artificial ...

Navin Wadhwani has stepped down as head of investment banking at JP Morgan India after just over two years. His duties will ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

JPMorgan’s net income soared 50% to more than $14 billion in the fourth quarter as the bank’s profit and revenue easily beat ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

According to JP Morgan analysts, if the SEC approves crypto ETFs, both XRP and Solana could attract up to $14bn in ...

With a new administration and crypto-friendly SEC chair on the horizon, J.P. Morgan analysts see potential for Solana and XRP ...

Banking giant Chase is chasing an ambitious goal these days – including a pledge to open more than 50 branches in ...